TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / 23andMe Stock

23andMe Stock

23andme.comHealthcareFounded: 2006Funding to Date: $876.61MM

23andMe is a consumer genetics and research company looking to help people access, understand, and benefit from the human genome.

Learn more about 23andMe IPO
Register for Details

For more details on financing and valuation for 23andMe, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for 23andMe.

Register Today

23andMe investors also invested in these private companies

Fidelity Investments
Casdin Capital
Altimeter Capital
Sequoia Capital

Team

Management Team

Steve Schoch
CFO
Kenneth Hillan, M.B., Ch.B
Head of Therapeutics
Anne Wojcicki
CEO & Co-Founder
Fred Kohler
Vice President, People
Kathy Hibbs JD
Chief Legal & Regulatory Officer
Mike Polcari
Vice President & Chief Architect

Board Members

Patrick Chung
Xfund
Roelof Botha
Sequoia Capital
Anne Wojcicki
23andMe
Neal Mohan
23andMe
Richard Scheller, Ph.D.
Self

Other companies like 23andMe in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Colossal Biosciences
Sector
Healthcare
 
 
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Synchron
Sector
Healthcare
Last Round Est. Valuation
$400.53MM
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
OURA
Sector
Healthcare
 
 
Cytonics
Sector
Healthcare
 
 
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
Precision Neuroscience
Sector
Healthcare
 
 

News

Genomeweb 01/18/2022
23andMe Study Associates Gene Locus With COVID-19-Related Loss of Smell, Taste
A multi-ancestry genome-wide association study found that genetics likely contributes to the loss of smell or taste in COVID-19 patients.
Genomeweb 10/29/2021
People in the News: New Appointments at Roswell Biotechnologies, 23andMe, Akoya Biosciences, More
Genomeweb 10/22/2021
23andMe to Acquire Telemedicine Platform Company Lemonaid Health for $400M in Cash, Stock
Lemonaid Health, based in San Francisco, offers a platform that provides online access to a variety of telemedicine and pharmacy services.

Trending Companies

Frequently Asked Questions